SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Avenue Therapeutics, Inc.
Beneficial Ownership Report (Schedule 13G)
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Avenue Therapeutics, Inc. as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Avenue Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 100,400 shares of Avenue Therapeutics, Inc. Common Stock.
- This ownership represents 4.99% of the outstanding class of securities.
- Armistice Capital, LLC, a Delaware entity, is an investment adviser and holds shared voting and dispositive power over all 100,400 shares.
- Steven Boyd, a U.S. citizen and managing member of Armistice Capital, LLC, also holds shared voting and dispositive power over the same 100,400 shares.
- The shares are held in the ordinary course of business and were not acquired for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a neutral, factual disclosure of beneficial ownership, typical for a Schedule 13G filing. It contains no positive or negative operational or financial news.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment firm and its principal, indicating a passive investment stake in Avenue Therapeutics, Inc. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, though passive, ownership stake by Armistice Capital, LLC and Steven Boyd. This indicates a notable institutional investor's position in the company.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (reporting period end date). |
| 02/14/2025 | Date of filing of the Schedule 13G Amendment No. 1. |
Keywords
Avenue Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.